Table 1.
Patients’ characteristics.
| Patient age, years, median (range) | 70 (36–84) | |
| Sex (n, %) | Male | 22 (61.1%) |
| Female | 14 (38.9%) | |
| Nephrectomy (n, %) | Yes | 29 (80.6%) |
| No | 7 (19.4%) | |
| Histology (n, %) | Clear cell | 27 (75.0%) |
| Clear cell + sarcomatoid | 3 (8.3%) | |
| Collecting duct | 2 (5.6%) | |
| Papillary | 1 (2.8%) | |
| Sarcomatoid | 1 (2.8%) | |
| MTSCC | 1 (2.8%) | |
| Unknown | 1 (2.8%) | |
| Treatment line (n, %) | First line | 2 (5.6%) |
| Second line | 21 (56.8%) | |
| Third line | 10 (27.8%) | |
| ≥Fourth line | 3 (8.3%) | |
| Prior therapy (n, %) | Sunitinib | 16 (44.4%) |
| Interferon-α | 12 (33.3%) | |
| Sorafenib | 8 (22.2%) | |
| Temsirolimus | 7 (19.4%) | |
| Everolimus | 7 (19.4%) | |
| Interferon-α + IL-2 | 1 (2.8%) | |
| Gemcitabine + Carboplatin | 1 (2.8%) | |
MTSCC mucinous tubular and spindle cell carcinoma, Treatment line treatment line of axitinib.